About Us
Driving DUB drug discovery and development
Since being established in 2009, Ubiquigent has cultivated an unrivalled track record and comprehensive range of specialist products and services focused on the exploitation of DUBs and the ubiquitin-proteasome system (UPS). As such, we are the partner chosen by many leading industry and academic organisations for their DUB-focused drug discovery and development programmes spanning the fields of protein degradation, stabilisation, and signalling.
Alongside the delivery of our products and services, we are developing an internal collection of compounds that can accessed through partnerships and out-licensing agreements by our clients as new starting points for their discovery programmes.
Ubiquigent is a revenue and IP-generating company that benefits from the support of its investors, including IP Group PLC and Scottish Enterprise. We’re located in Dundee, Scotland, where we sit at the centre of a growing hub of highly relevant scientific expertise and capabilities.






